Therefore, this pathway has been pursued as a therapeutic strategy for inhibition of lymphangiogenesis and metastatic in tumors,and some animal studies have shown that the expression of VEGF-D promotes lymphangiogenesis and metastatic spread of tumor cells via lymphatic in papillary thyroid carcinoma, lung cancer and gastric cancer [32–34]. This evidence concerns the gene VEGFD and differentiated thyroid carcinoma.